Current immunosuppression strategies in pediatric heart transplant

References

• 1. Kirk R, Edwards LB, Aurora P et al. Registry of the International Society for Heart and Lung Transplantation: Twelfth Official Pediatric Heart Transplantation Report-2009. J. Heart Lung Transplant. 28(10), 993–1006 (2009).
  MedlineGoogle Scholar
• 2. Canter CE, Shaddy RE, Bernstein D et al. Indications for heart transplantation in pediatric heart disease: a scientific statement from the American Heart Association Council on cardiovascular disease in the young; the Councils on Clinical Cardiology, Cardiovascular Nursing, and Cardiovascular Surgery and Anesthesia; and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation 115(5), 658–676 (2007).
  MedlineGoogle Scholar
• 3. Di Filippo S, Boissonnat P, Sassolas F et al. Rabbit antithymocyte globulin as induction immunotherapy in pediatric heart transplantation. Transplantation 75(3), 354–358 (2003).
  MedlineGoogle Scholar
• 4. Irving CA, Webber SA. Immunosuppression therapy for pediatric heart transplantation. Curr. Treat. Options Cardiovasc. Med. 12(5), 489–502 (2010).
  MedlineGoogle Scholar
• 5. Butts RJ, Dipchand AI, Sutcliffe D et al. Comparison of basiliximab vs antithymocyte globulin for induction in pediatric heart transplant recipients: an analysis of the International Society for Heart and Lung Transplantation database. Pediatr. Transplant. 22(4), e13190 (2018).
  MedlineGoogle Scholar
• 6. Cochrane AB, Lyster H, Lindenfeld J et al. Report from the 2018 consensus conference on immunomodulating agents in thoracic transplantation: access, formulations, generics, therapeutic drug monitoring, and special populations. J. Heart Lung Transplant. 39(10), 1050–1069 (2020).
  MedlineGoogle Scholar
• 7. Simmonds J, Dewar C, Dawkins H, Burch M, Fenton M. Tacrolimus in pediatric heart transplantation: ameliorated side effects in the steroid-free, statin era. Clin. Transplant. 23(3), 415–419 (2009).
  MedlineGoogle Scholar
• 8. Robinson BV, Boyle GJ, Miller SA et al. Optimal dosing of intravenous tacrolimus following pediatric heart transplantation. J. Heart Lung Transplant. 18(8), 786–791 (1999).
  Medline CASGoogle Scholar
• 9. D'addese L, Joong A, Burch M, Pahl E. Pediatric heart transplantation in the current era. Curr. Opin. Pediatr. 31(5), 583–591 (2019).
  MedlineGoogle Scholar
• 10. Eisen HJ, Kobashigawa J, Keogh A et al. Three-year results of a randomized, double-blind, controlled trial of mycophenolate mofetil versus azathioprine in cardiac transplant recipients. J. Heart Lung Transplant. 24(5), 517–525 (2005).
  MedlineGoogle Scholar
• 11. Gajarski RJ, Crowley DC, Zamberlan MC, Lake KD. Lack of correlation between MMF dose and MPA level in pediatric and young adult cardiac transplant patients: does the MPA level matter? Am. J. Transplant. 4(9), 1495–1500 (2004).
  Medline CASGoogle Scholar
• 12. Gustafsson F, Andreassen AK, Andersson B et al. Everolimus initiation with early calcineurin inhibitor withdrawal in de novo heart transplant recipients: long-term follow-up from the randomized SCHEDULE study. Transplantation 104(1), 154–164 (2020).
  Medline CASGoogle Scholar
• 13. Raichlin E, Bae JH, Khalpey Z et al. Conversion to sirolimus as primary immunosuppression attenuates the progression of allograft vasculopathy after cardiac transplantation. Circulation 116(23), 2726–2733 (2007).
  Medline CASGoogle Scholar
• 14. Asante-Korang A, Carapellucci J, Krasnopero D, Doyle A, Brown B, Amankwah E. Conversion from calcineurin inhibitors to mTOR inhibitors as primary immunosuppressive drugs in pediatric heart transplantation. Clin. Transplant. 31(10), (2017).
  MedlineGoogle Scholar
• 15. Rosenthal LM, Nordmeyer J, Kramer P et al. Long-term experience using CNI-free immunosuppression in selected paediatric heart transplant recipients. Pediatr. Transplant. 25(8), e14111 (2021).
  MedlineGoogle Scholar
• 16. Smith RR, Wray J, Khaghani A, Yacoub M. Ten year survival after paediatric heart transplantation: a single centre experience. Eur. J. Cardiothorac. Surg. 27(5), 790–794 (2005).
  MedlineGoogle Scholar
• 17. Singh TP, Faber C, Blume ED et al. Safety and early outcomes using a corticosteroid-avoidance immunosuppression protocol in pediatric heart transplant recipients. J. Heart Lung Transplant. 29(5), 517–522 (2010).
  MedlineGoogle Scholar
• 18. Pollock-Barziv SM, Den Hollander N, Ngan BY et al. Pediatric heart transplantation in human leukocyte antigen sensitized patients: evolving management and assessment of intermediate-term outcomes in a high-risk population. Circulation 116(Suppl. 11), I172–178 (2007).
  MedlineGoogle Scholar
• 19. Kaposztas Z, Podder H, Mauiyyedi S et al. Impact of rituximab therapy for treatment of acute humoral rejection. Clin. Transplant. 23(1), 63–73 (2009).
  Medline CASGoogle Scholar
• 20. Morrow WR, Frazier EA, Mahle WT et al. Rapid reduction in donor-specific anti-human leukocyte antigen antibodies and reversal of antibody-mediated rejection with bortezomib in pediatric heart transplant patients. Transplantation 93(3), 319–324 (2012).
  Medline CASGoogle Scholar